New Approaches to Evaluate And Optimize Older Patients for Transplant (Allogeneic)

Similar documents
Workshop I: Patient Selection Current indication for HCT in adults. Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan

Biol Blood Marrow Transplant 19 (2013) 429e434

4/26/2012. Laura Grooms, MD Assistant Professor Geriatric Medicine Department of Family and Geriatric Medicine University of Louisville April 20, 2012

Biologic vs physiologic age in the transplant candidate

Comorbidities in Multiple Myeloma

Survivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life

Communicating Treatment Options to Older Patients: Challenges and Opportunities

Getting Fit for Transplant. Thuy Koll, MD Assistant Professor Division of Geriatrics Department of Internal Medicine

CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints

Comparing outcome between Belgian haematopoietic stem cell transplant centres

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand

Stem cell transplantation in elderly, but fit multiple myeloma patients

Summary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016

Blood & Marrow Transplantation Center

Meet the Professor Dosing and toxicity management

UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma

An Overview of Blood and Marrow Transplantation

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

Integrating Geriatrics into Oncology Care

Developing a Quality Dashboard An Evidence Based Approach PURPOSE/OBJECTIVES:

HCT for Myelofibrosis

Haplo vs Cord vs URD Debate

The SOCARE Model of Cancer Care for Older Adults: Building Infrastructure and Policies for Truly Personalized Cancer Care for an Aging Society

Management of Multiple Myeloma: The Changing Paradigm

Why Geriatric Oncology?

By: Mei-Jie Zhang, Ph.D.

Late effects, health status and quality of life after hemopoietic stem cell

State of the Art Treatment for Relapsed Mantle Cell Lymphoma

Geriatric screening tools in older patients with cancer

Transplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust

Risk stratification in the older patient; what are our priorities?

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen

Survivorship After Stem Cell Transplantation and Long-term Followup

Dr. Joyita Banerjee PhD Scholar Dept. of Geriatric Medicine AIIMS, New Delhi, India

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa

Reduced-intensity Conditioning Transplantation

Late complications after hematopoietic stem cell transplant in adult patients

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016

PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey

Myeloma Support Group: Now and the Horizon. Brian McClune, DO

Frailty in Older Adults

Geriatric Assessment to Improve Outcomes for Older Adults with Cancer

Management of the Frail Older Patients: What Are the Outcomes

STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA

Donatore HLA identico di anni o MUD giovane?

INTEGRATED GERIATRIC AND PRIMARY CARE MANAGEMENT OF FRAIL OLDER ADULTS IN THE COMMUNITY

Stem Cell Transplantation for Severe Aplastic Anemia

Outline Pretransplant Essential data Why comorbidities are important? For patients with cancer For patients given allogeneic HCT

Long-Term Outcomes After Hematopoietic Cell Transplantation

Bone Marrow Transplantation and the Potential Role of Iomab-B

GERIATRIC ONCOLOGY. An Introduction. Dr Lissandra Dal Lago, MD, PhD Dr Noam Pondé, MD Institut Jules Bordet, Brussels, Belgium

Integrating Palliative and Oncology Care in Patients with Advanced Cancer

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University

Late effects after HSCT

Related haploidentical donors versus matched unrelated donors

Stem cell Survivorship: Searching for a solution to our success. Rich Boyajian NP Clinical Director of the LAF ad u lt su rvivorship clinic

Review of Stem Cell Collection Data 2016 Ronan Foley, Professor, Director Stem Cell Laboratory, McMaster University

Frailty in Older Adults. Farshad Sharifi, MD, MPH Elderly Health Research Center

3/6/2017. Objectives. Prehabilitation Training the Frail. I have no financial relationships with commercial interests to disclose.

Preoperative Assessment Guidelines in the Elderly

Protecting Your Health After Transplant (Adults)

Frailty: Challenges and Possible Solutions

The Blood & Marrow Transplantation Center

An Introduction to Bone Marrow Transplant

OF LIFE AMONG OLDER ADULTS WITH HEMATOLOGIC MALIGNANCIES

Improving the Survivorship of Older Adults with Cancer Using Geriatric Assessment

ASBMT MDS/MPN UPDATE

HEMATOPOIETIC CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA

Pre-transplant emotional support is associated with longer survival after allogeneic hematopoietic stem cell transplantation

Check out ASH s VIDEO LIBRARY for Useful Teaching Tools

Frailty Assessment: Simplifying the Complex

Capacity Analysis in a Specialized Service: Mapping the Future

ADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES

Frailty, Sarcopenia and Outcomes after Emergency Surgery Admissions Across Wessex

Dementia through a lens of Social Vulnerability. Melissa K. Andrew, MD, PhD, MSc(PH), FRCPC Geriatric Medicine Dalhousie University

Late Complications. Navneet Majhail, MD, MS

Late Complications. Objectives. Long-term Survival after HCT. Long-term Survival and Late Complications after HCT. Long-term Survival after HCT

Test and Learn Community Frailty Service for frail housebound patients and those living in care homes in South Gloucestershire

Cancer Treatment in Elderly Patients. Greg Hart Clinical Oncologist GVI Oncology

Outcome of patients with hematologic malignancy admitted to the ICU

Transplant Outcomes and Referral Guidelines

Who is at risk? What should we do in the clinic?

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

Patient Input CADTH COMMON DRUG REVIEW

Induction Therapy & Stem Cell Transplantation for Myeloma

Breast cancer in the elderly - is there a role for the geriatrician?

Corporate Medical Policy

What is frailty and why it is important

Pre- Cardiac intervention. Dr. Victor Sim 26 th Sept 2014

Aging: Tools for Assessment

Frailty in Older Mexican Americans

Myelodysplastic syndrome. Jeanne Palmer, MD Mayo Clinic, Arizona

Home based hematopoietic stem cell transplantation

4nd Patient and Family Day

The Role of Outcomes Registries in Blood and Marrow Transplantation Mary M Horowitz, MD, MS Cape Town, South Africa November 2014

The Blood and Marrow. Transplant Program at Northside Hospital 30%

Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation

Kidney Transplant in the Elderly. Robert Santella, M.D., F.A.C.P.

Should lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France

Transcription:

New Approaches to Evaluate And Optimize Older Patients for Transplant (Allogeneic) Andrew S. Artz, MD, MS Associate Professor of Medicine Clinical Director, Hematopoietic Cellular Therapy Program University of Chicago Center for Care and Discovery

Outline The influence of Age on MDS and Transplant Use Using Physiologic Age to Inform and Optimize Older Transplant Patients: The Chicago Experience Physiologic vs Chronologic 2

Survey: What Age Does A Person Become Old? Aging and Transplant 3

Incidence of MDS per age group Transplant in Older Adults 4

Aging and Transplant

The Transplant Triad: Influence of Older Age Disease More frequent More difficult disease to control Older sibling donors Use gentler regimen More Health Issues Long-term benefits unclear Donor and Regimen Patient

Allogeneic Transplant Trends for Age 70 and Greater by Disease Absolute No. HCTs 70 Years 7 Muffly L, BMT Tandem 2016 on behalf of CIBMTR, manuscript submitted Also see abstracts 678 and 673, ASH 2016 Aging and Transplant

Calendar Age versus Physiologic Age Stock photo Dr. Artz found on internet Chau Smith- 7 marathons, 7 days, 7 continents age = 70 Physiologic vs Chronologic

Staging the Age: Geriatric Assessment Domain Measured Comorbidity Polypharmacy Physical Function Psychological Health Cognition Social Support Nutrition Lawton Instrumental Activities of Daily Living (independence in these tasks) Ability to use the telephone Shopping Food preparation Mode of Transportation Manages medications Manages finances Housekeeping Medical History and testing (e.g, diabetes) Number of medications Patient survey and Bedside Tests Patient survey Provider asking patient questions Patient survey Patient survey *modified from Hurria, JCO 2011 29(25): 3457-3465 Aging and Transplant

Candidacy: To transplant or not to transplant Physiologic vs Chronologic 10

Standard Transplant Exclusions Factor Auto Transplant (Stamina 0702) Allo Transplant (BMT CTN 0502) Age >70 >74 Heart X X Liver Function X X Kidney X X Lungs X X Other cancer <5 years N/A MD rated Function X X LBA-1, ASH 2016, Stadtmauer E.A. Comparison of Autologous Devine S, J Clin Oncol 33(35) 4165-4175 Transplant In Older Adults

High Prevalence of Vulnerabilities by Geriatric Assessment prior to Transplant: Pts 50+ GA Toolbox Frailty: Fried Frailty Index PCS: SF 36 Physical component score MCS: SF-36 Mental component score IADL: Instrumental activities of daily living HCT-CI: Hematopoietic cell transplantationcomorbidity index CIRS: Cumulative Illness rating scale-geriatrics CRP-C-reactive protein Muffly L, Biol Blood marrow Transplant, 2013 19(3):429-434 Also see Holmes H.M., J Geriatr Oncol: 2014 5(4):422-430

Transplant Success: Listen to thy patient Very Important Function by questions, high measure of inflammation or low albumin Intermediate Other conditions (comorbidity), disease control, slow walk speed Muffly L,Haematologica, 2014 13

Proposed Transplant Eligibility For Patients 60+ Factor Auto High/Exclude or trial Allo High/Exclude or trial Age 70+/ >79 >60/ >79 Disease Not controlled Not controlled KPS (%) 60-70/<60 70-80/<70 Comorbid Cognitive Impair Function severe or HCT-CI 5+/none Mild/ Moderate IADL limitation, Frail function, falls /combination HCT-CI 3-4/ 5+ or Severe Mild/Moderate IADL limitation,frail function, falls /combination HCT-CI: hematopoietic cell transplantation comorbidity index, KPS-Karnofsky performance score, IADL: Instrumental activity of daily living Aging and Transplant

Optimization: A case study 41 71 year old female with MDS (IPSS intermediate 2) potential perfect matched unrelated donor MD function-ok (KPS-80%), Diabetes, depression Other symptoms: forgetful at times, knee and hip pain, Social: Widowed, children in area Physiologic vs Chronologic 15

Eligibility to Resilience: Transplant Optimization Program (TOP) for older adults Transplant Candidate 60+ Geriatric Assessment Transplant MD and APN Social Work Physical Therapy Dietician Geriatric Oncology Cognitive testing (after TOP) Interdisciplinary Meeting Physiologic vs Chronologic 16

TOP: GA to Inform and Optimizing Transplant Domain Comments Vulnerability (V) or Asset (A) Plan Comorbidity Functional Diabetes, Depression, arthritis, kidney function mild impaired Good strength, limited endurance V endocrine on admit Change arthritis medication +/- Pre-habilitation with PT Cognition Normal A Detailed education in writing Emotional Health Coping, anxiety V Engage family, psych referral Social support Initially poor, later strong A Family meeting Caregivers in room Nutrition No weight loss, partial dentures A Educate on supplements Polypharmacy 3 Rx medication One supplement A Safety of other medications, stop supplement Transplant in Older Adults 17

Conclusions Calendar age important but physiologic age essential to guide decision to pursue transplant in older patients Multi-disciplinary team approach tailored to physiologic age holds promise to expand transplant and transplant success for older adults Physiologic vs Chronologic 18

Acknowledgements-Too Many Thanks University of Chicago Transplant Team Program Director: M. Bishop MDs-Transplant, Leukemia, Myeloma and Lymphoma Transplant Coordinators Fellows, residents and interns: Transplant Optimization Program Geriatrics: S. Chow, W. Dale., J. Wallace Dietician: V. Reynolds, L. Chavez CRA: J. Scott, A. Small NP: J. Ridgeway PT: B. Campione, R. Spigel ID: J. Pisano Social Work: M. Paloma L. Balducci and Organizers!!!! Physiologic vs Chronologic 19